Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Rong Hua

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2477-3764; OpenAlex author ID A5101582267. Sources: OpenAlex.

Their work

Papers
32 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2013: 1 paper · 2014: 3 papers · 2015: 5 papers · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: 4 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers

Papers 32

  1. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  2. The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway. Co-author DOI 10.1186/s12935-024-03440-z↗
  3. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11427-022-2146-5↗
  4. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  5. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  6. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. Co-author DOI 10.1002/1878-0261.12970↗
  7. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  8. ERO1L Promotes Hepatic Metastasis through Activating Epithelial-Mesenchymal Transition (EMT) in Pancreatic Cancer. Co-author DOI 10.1155/2021/5553425↗
  9. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  10. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  11. Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-20-0111↗
  12. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11866↗
  13. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer. Last author DOI 10.7150/thno.45124↗
  14. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Co-author DOI 10.1038/s41419-019-2072-5↗
  15. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  16. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  17. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. Co-author PMID 30906634↗
  18. Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients. Co-author DOI 10.3892/ol.2018.8452↗
  19. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384101.2017.1356510↗
  20. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. Co-author DOI 10.7150/jca.20086↗
  21. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep33535↗
  22. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.6772↗
  23. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. Co-author PMID 27648368↗
  24. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep10575↗
  25. Corrigendum: Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep15869↗
  26. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-015-0202-1↗
  27. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.5939↗
  28. High expression of WISP-1 correlates with poor prognosis in pancreatic ductal adenocarcinoma. Co-author PMID 26550461↗
  29. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC. Co-author DOI 10.1016/j.pan.2014.07.013↗
  30. Effect of CD74 on the prognosis of patients with resectable pancreatic cancer. First author DOI 10.1016/s1499-3872(14)60011-4↗
  31. MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Last author PMID 25520858↗
  32. Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer. First author DOI 10.7314/apjcp.2013.14.9.5133↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 29 shared papers, 2014–2024 · strength 2.46
  2. Yan‐Miao Huo · 27 shared papers, 2014–2024 · strength 2.39
  3. Jian‐Yu Yang · 24 shared papers, 2014–2024 · strength 2.08
  4. Minwei Yang · 19 shared papers, 2015–2024 · strength 1.71
  5. Xueliang Fu · 19 shared papers, 2015–2024 · strength 1.65
  6. Dejun Liu · 18 shared papers, 2014–2024 · strength 1.59
  7. Junfeng Zhang · 11 shared papers, 2016–2023 · strength 1.11
  8. Shu‐Heng Jiang · 10 shared papers, 2015–2023 · strength 0.92
  9. Junfeng Zhang · 10 shared papers, 2014–2024 · strength 0.82
  10. Zhigang Zhang · 9 shared papers, 2015–2023 · strength 0.71
  11. Jia-Hao Zheng · 4 shared papers, 2022–2024 · strength 0.62
  12. Hong‐Fei Yao · 4 shared papers, 2022–2024 · strength 0.62
  13. Wei Chiang Liu · 6 shared papers, 2013–2022 · strength 0.53
  14. Ruizhe He · 5 shared papers, 2019–2022 · strength 0.48
  15. Wei Liu · 5 shared papers, 2014–2024 · strength 0.45
  16. Zong‐Hao Duan · 2 shared papers, 2024 · strength 0.36
  17. Qin-Yuan Jia · 2 shared papers, 2024 · strength 0.36
  18. Wei Liu · 2 shared papers, 2020–2024 · strength 0.29
  19. Li-Peng Hu · 3 shared papers, 2019–2022 · strength 0.27
  20. Dejun Liu · 4 shared papers, 2016–2019 · strength 0.25
  21. Wei Liu · 2 shared papers, 2021–2022 · strength 0.24
  22. Jie Hong · 5 shared papers, 2014–2017 · strength 0.24
  23. Jianyu Yang · 2 shared papers, 2015–2024 · strength 0.23
  24. Rongkun Li · 2 shared papers, 2019–2023 · strength 0.23
  25. Qin Yang · 2 shared papers, 2019–2023 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.